Diabetes
Researchers from University of Birmingham provide details of new studies and findings in the area of diabetes
Published in Medical Verdicts and Law Weekly, July 24th, 2008
According to recent research from Birmingham, the United Kingdom, " To examine the impact of inhaled human insulin (Exubera (R), EXU) on patient or physician willingness to adopt insulin after oral glucose-lowering agent failure. During a randomized controlled trial in primary, secondary and tertiary care in Europe and North America, 739 patients using >= 2 oral glucose-lowering agents with glycated haemoglobin (HbA(1c)) >= 8.0% were assigned to two treatment groups: Group 1 (standard care with the option of EXU) or Group 2 (standard care only)."
"Standard care included adjusting oral therapy (optimizing current regimen or adding/omitting agents) and/or...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
More Articles from Medical Verdicts and Law Weekly
- American Association of Cheerleading Coaches and Administrators
The American Association of Cheerleading Coaches & Administrators Announce New Safety Rules - American Association of People With Disabilities
Historic Presidential Forum Unites Thousands in Disability Community - American Association of Port Authorities AAPA
AAPA Hails Passage of Vessel Air Emissions Bill - American Health Information Management Association
Mitigating Medical Identity Theft: AHIMA Journal Provides Patient Tools to Secure Health Information - American Institute of Certified Public Accountants AICPA
New Guidelines Aim to Reduce Fraud - American Legacy Foundation
American Legacy Foundation(R) Statement of Support for the Federal Trade Commission Reversal on Tar and Nicotine Yield Statements on Cigarettes - More from this issue of Medical Verdicts and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
